Kornimate/medical-research-clean huggingface dataset:
radiofrequency in female pattern hair loss

Conditions: Female Pattern Baldness

Summary: pattern hair loss, also called androgenetic alopecia (aga) is considered the most common cause of hair loss in both males and females affecting approximately 85% of males and 50% of females over 50 years of age.

rf (radiofrequency) based devices have also been shown to be successful in promoting hair growth, thought to occur through the induction of growth factors in the papillary dermis. studying the effect of fractional needling radiofrequency in the treatment of female pattern hair loss will pave the way for more treatment options for this common disease.

Eligibility criteria:
inclusion criteria: * patients with female pattern hair loss exclusion criteria: * - pregnancy and lactation. * bleeding tendency. * cases who received treatment (systemic or topical) in the last 3 months before treatment. * scarring alopecia. * other associated causes of alopecia
cognitive dysfunction in people who are obese but metabolically healthy

Conditions: Metabolic Syndrome

Summary: there is some evidence to suggest that obesity is a risk factor for the development of cognitive dysfunction, although this is not a universal finding. this discordance might be ascribed to the existence of a 'healthy obese phenotype'- that is, obesity in the absence of metabolic risk factors. we examined whether the association of obesity with cognitive dysfunction is dependent on the individual's metabolic health. 60 obese patients' undergoping liver fibroscan and blood tests will be enrolled. obesity was defined as body mass index ≥ 30 kg/m2. based on blood pressure, hdl-cholesterol, triglycerides, glycated haemoglobin, and c-reactive protein, participants were classified as 'metabolically healthy' (0 or 1 metabolic abnormality) or 'unhealthy' (≥ 2 metabolic abnormalities). cognitive dysfunction will be assessed by moca and minimental score. results: cognitive dysfunction prevalence is expected in 30% , but 50% of this group was categorized as metabolically healthy. relative to non-obese healthy participants, after adjustment for baseline covariates, the metabolically unhealthy obese participants had elevated risk of cognitive dysfunction although the metabolically healthy obese did not. the association between obesity and risk of cognitive dysfunction appears to be partly dependent on metabolic health, although further work is required to confirm these findings. in obesity there is an increase in oxidative stress due to metabolic syndrome . thus obese patients suffer from higher incidences of cardiovascular complications such as atherosclerosis as compare to non- obese population. haptoglobin (hp) is a plasma protein which binds free hemoglobin and prevents it from heme- iron mediated oxidation. there are three different types of hp which differ in their antioxidant ability. several clinical studies have shown that hp 2-2 genotype is associated with higher incidence of cardiovascular diseases.


Eligibility criteria:
inclusion criteria: freely given written informed consent bmi\>=30 exclusion criteria: evidence of chronic liver diseases pregnant women
efficacy and safety study of cd 2027 spray in subjects with plaque-type psoriasis

Conditions: Psoriasis

Summary: this was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of cd 2027 oily spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of plaque-type psoriasis up to 20% of body surface area (bsa) involved excluding the scalp, with a global severity score of at least 3 (moderate) at screening * participant presents with a representative target lesion that is at least 16 cm² in area, is located on the non-bony areas of the skin, has a scaling score up to 2 (moderate), has a dss of at least 4 exclusion criteria: * other type of psoriasis (other than plaque) * significant abnormal lab findings * hypercalcemia

Keywords: psoriasis spray calcitriol
multicomponent therapy for fibromyalgia

Conditions: Fibromyalgia

Summary: therapy for fibromyalgia is a well discussed topic in literature, yet not thoroughly evidence-based. several unicomponent therapies seem to be benificial. whereas multicomponent and multidisciplinary therapy gains importance and revealing promising results, the investigators aim to combine two well-known therapies in a program for patients with fibromyalgia. from clinical experience, a high drop-out rate has been stated. all data will be explored to analyse explanatory factors.


Eligibility criteria:
inclusion criteria: * woman with fibromyalgia * between the age of 20 and 50 * agreement with therapy protocol exclusion criteria: * high indication of depression measured with the beck depression index

Keywords: multicomponent therapy
lacosamide in neonatal status epilepticus

Conditions: Epilepsy

Summary: lacosamide in neonatal status epilepticus

the study will assess the efficacy of lacosamide in neonatal status epilepticus

Eligibility criteria:
inclusion criteria: * neonates with status epilepticus exclusion criteria: * congenital anomalies or organ dysfunction
mk6186 in hiv-1 infected patients (mk-6186-007 am2)

Conditions: HIV-1 Infection

Summary: this study will evaluate the safety and tolerability of mk6186 and the change from baseline in plasma hiv-1 rna after seven consecutive days of dosing.


Eligibility criteria:
inclusion criteria: * other than hiv infection, patient's baseline health is judged to be stable * patient is documented hiv-1 positive * patient has not received an investigational agent or licensed art with in the past 30 days exclusion criteria: * patient has a history of stroke, chronic seizures, or major neurological disease * patient has a history of cancer * patient has used any immune therapy agents or immunosuppressive therapy within the past month * patient requires or anticipates the use of any prescription or non-prescription drugs during the study * patient has a current diagnosis of acute hepatitis, has a history of hepatitis c or has positive hepatitis b surface antigen * patient consumes excessive amounts of alcohol (greater than 3 servings per day) or caffeine (greater than 6 servings per day) * patient is an excessive smoker (more than 10 cigarettes per day) * patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks

Keywords: treatment of hiv-1 infection
earlier mobilization post acute thrombectomy

Conditions: Stroke; Stroke, Acute; Stroke, Ischemic

Summary: this is a phase iii trial trying to determine whether 12-hour bed rest following thrombectomy for ischemic stroke is non-inferior to 24-hour bed rest by measure of outcomes on the modified rankin scale (mrs) at 90 days post bed rest.


Eligibility criteria:
inclusion criteria: * age 18 years or older * received thrombectomy (may have also received intravenous tpa) for a diagnosis of acute ischemic stroke * tici 2b/2c/3 score following thromectomy * patient and/or legally authorized representative provide consent exclusion criteria: * tici 0/1/2a score following thrombectomy * venous thromboembolism present at symptom onset * pneumonia present at symptom onset * stemi at symptom onset * positive troponins at symptom onset according to local values * bone fracture at symptom onset * intubation anticipated or occurred * symptomatic intracranial hemorrhage (defined as increase in nihss by 4 points or more accompanied by ph2 hemorrhage on imaging) at the time of screening. * pre-screening systolic blood pressure \< 110 mmhg * resting pulse oximetry \< 92% (with or without supplemental oxygen) * neurological worsening (defined as nihss increase of 4 points compared to initial score) prior to screening. * baseline modified rankin scale score \> 2 * known pregnancy * patient not anticipated to survive 3 months * patient not anticipated to follow-up at 3 months

Keywords: mobilization thrombectomy ischemia cerebrovascular disorders brain diseases recovery
increasing adherence to follow-up of breast abnormalities in low-income korean american women

Conditions: Breast Cancer

Summary: develop and evaluate a peer navigator intervention to assist korean women with a potential breast abnormality, who have missed their first follow-up appointment, to complete all diagnostic follow-up tests.

the purpose of this study is to design an intervention to assist korean american women who have been identified with a potential breast abnormality through the breast cancer early detection program and who have missed their first follow-up appointment (at risk women). intervention activities will include reminder phone calls or home visits by a trained peer navigator to explain the importance of follow-up procedures, emotional support, help with transportation to follow-up appointments, translations, organizing care for children or grandchildren during medical appointments, and other assistance to overcome barriers to follow-up identified during the initial phase of the study. the investigators will collect extensive process measures including number and type of intervention activities requested and delivered in order to estimate the feasibility for institutionalizing intervention activities. the investigators will conduct chart reviews and a follow-up survey to evaluate the effectiveness of the intervention in increasing adherence to follow-up procedures.

Eligibility criteria:
inclusion criteria: * being: a korean american woman * screened through the breast cancer early detection program * with a potential breast abnormality * having missed a first diagnostic follow-up appointment exclusion criteria: * not a korean american woman * not screened through the breast cancer early detection program * no potential breast abnormality * not having missed a first diagnostic follow-up appointment

Keywords: follow-up of breast abnormalities korean american immigrants
study to assess efficacy and safety of zoledronic acid and the value of markers of bone resorption in the prediction of bone metastases and cancer treatment-induced bone loss (ctibl) in patients with prostate cancer on hormone therapy

Conditions: Cancer Prostate

Summary: the objective of the study is to investigate whether blood markers can be used to predict the development of bone metastases and to assess the efficacy and safety of zoledronic acid in cancer treatment induced bone loss.


Eligibility criteria:
inclusion criteria: * all stages of prostate cancer without bone metastases * no evidence of severe osteoporosis * ecog performance status 0, 1 or 2 exclusion criteria: * surgery / fracture at the lumbosacral spine, bilateral hip implants * evidence of metabolic bone diseases, * treatment with bisphosphonates or calcitonin within the previous year or chronic systemic corticosteroid treatment * abnormal kidney or liver function * other cancers within the last 5 years other protocol-defined exclusion criteria may apply.

Keywords: zoledronic acid zometa prostate cancer osteoporosis
personalized molecular profiling in cancer treatment at johns hopkins

Conditions: Metastatic Breast Cancer

Summary: the goal of this research study is to determine if we can obtain personalized genetic information from a subject's blood sample that is similar to that obtained from a tumor tissue sample, and if we can use that information to make treatment suggestions.

the goal of this research study is to determine if we can obtain personalized genetic information from a subject's blood sample that is similar to that obtained from a tumor tissue sample, and if we can use that information to make treatment suggestions. as tumor samples can be difficult to collect, we hope to be able to collect similar genetic information from blood or urine samples that we find in tumor tissue. ultimately, we hope to identify genes important to cancer cells that could potentially identify standard-of-care or research-based recommendations for therapy.

Eligibility criteria:
inclusion criteria: * male or female * 18 years of age or older * metastatic breast cancer and treatment with prior chemotherapy * any clinical phenotype (triple negative, hormone receptor positive, human epidermal growth factor receptor 2 (her2)-positive) * patient must have received a metastatic tumor biopsy within 3 years prior to the date of the first planned blood sample for the study and have tissue available from this biopsy * able to voluntarily provide informed consent exclusion criteria: * women who are pregnant or nursing

Keywords: metastatic breast cancer breast cancer molecular profiling personalized medicine
depression treatment and risk for cardiovascular disease

Conditions: Depression

Summary: this study was designed to determine the feasibility of a randomized controlled trial (rct) that involved treating depression among participants with an elevated risk for cardiovascular disease. it is expected that treating depression through non-pharmacological means will impact heart rate variability, a proximal measure of cvd risk.


Eligibility criteria:
inclusion criteria: males and females age 21-75 meet diagnostic criteria for major depressive disorder framingham risk score indicating a greater than negligible 10-year risk (3% or greater) for cardiovascular disease. levels of depressive symptoms of at least moderate level (beck depression inventory ii score \> 19 of 63 possible points; or a hamilton depression rating scale \> 12 of 50 possible points) exclusion criteria: a verbal expression of current, significant, suicidal ideation; a score of \> 15 on the beck scale for suicidal ideation score of \>1 on any single item of the beck scale for suicidal ideation score of \> 1 on the item assessing suicidal ideation on the beck depression inventory ii. psychiatric diagnoses that could potentially interfere with depression treatment (current post traumatic stress disorder, bipolar i disorder, obsessive-compulsive disorder, bulimia or anorexia nervosa, schizophrenia, and panic disorder) current use of an antidepressant medication currently in psychotherapy. current use of a beta blocker, anxiolytic (benzodiazepine), antipsychotic agent diagnosis of cvd.
comparison of hyaluronic acid and corticosteroid intra-articular injections for the treatment of osteoarthritis of the hip

Conditions: Coxarthrosis

Summary: abstract background: the effect of intra-articular treatment of hip osteoarthritis with hyaluronic acid in the hip joint is not based on large randomized controlled trials. hyaluronic acid is a well established treatment for osteoarthritis of the knee. methods: randomized controlled trial with three-armed parallel-group design. the patients meeting the inclusion criteria will be randomized into one of the following groups: infiltration of the hip joint with hyaluronic acid, with corticosteroids or with bupivacaine 0,125%. pain vas, harris hip score and hoos were scored during follow-up. the patients will be asked to determine their situation as worse, stabile or better then at the time of enrollment. there will be asked if they use painkillers and if they have complications/adverse events. these outcome measure instruments will be used at the time of enrollment in the study prior to any injection, and then again at six weeks, 3 and 6 months after the initial injection. the six-month follow-up period begins for all patients on the date the first injection will be administered.


Eligibility criteria:
inclusion criteria: 1. an age between 30 and 70years 2. radiographic evidence of oa of the hip (kellgren-lawrence grading scale 1-3) 3. chronic pain for at least 3 months prior to study entry (day 0) 4. dissatisfaction with prior attempts at non-operative management including nonsteroidal anti-inflammatory drugs. exclusion criteria: 1. kellgren and lawrence grade 4 2. an intra-articular hip injection (with any corticosteroid, hyaluronic acid preparation or other) within the previous three months 3. non compliance to the study procedures and or non completion of the study according to investigator's judgment 4. rapid destructive hip. 5. a history of crystalline arthropathy or inflammatory arthritis, neuropathic arthropathy 6. a current other problem in the affected extremity 7. contra-indications for the use of corticosteroids (gastrointestinal ulcer, severe osteoporosis, psychiatric anamnesis, herpes simplex or zoster (viremic stadium), varicella, 8 weeks before and 2 weeks after immunization, systemic mycosis, poliomyelitic except of bulbar encephalitic form lymphadenitis after bcg-vaccination, parenteral depot medication, closed- and wide-angle glaucoma) 8. allergy or hypersensitivity to any of the study medications or to contrast solutions.

Keywords: coxarthrosis hip infiltration hyaluronic acid corticosterone
acute stroke program of interventions addressing racial and ethnic disparities

Conditions: Stroke

Summary: the purpose of this study is to increase treatment of acute stroke with tissue plasminogen activator (tpa) across the district of columbia. this study, however, will not evaluate tpa as an intervention.

there are a number of well-known barriers to receiving tissue plasminogen activator (tpa) including transit time to hospital, paramedic and provider training, tpa standing orders, and provider guidelines. among underserved populations, limited stroke knowledge, socioculturally determined attitudes, and beliefs and myths held by community members may serve as additional barriers that hinder these populations from receiving tpa and acute stroke care. targeted multilevel interventions designed to overcome specific barriers may significantly increase the number of individuals with stroke who are appropriately treated with intravenous tpa (iv tpa) in underserved communities. identification of the specific components of healthcare interventions that are the most effective is critical to improve delivery of acute stroke therapy. the goal of this study is to learn more about public knowledge, attitudes, beliefs and perceptions regarding stroke and stroke treatment in order to identify sociocultural and environmental barriers to receiving tpa and acute stroke care in an underserved community. this study will also determine if implementation of a multilevel intervention program can significantly increase the number of people with ischemic stroke who are appropriately treated with iv tpa in a predominantly underserved community. in the study, researchers will evaluate the different levels of the intervention to determine which efforts are most effective.

Eligibility criteria:
inclusion criteria: * diagnosis of acute ischemic stroke * over the age of 18 exclusion criteria: -

Keywords: stroke tissue plasminogen activator tpa
postoperative analgesia after minithoracotomy

Conditions: Postoperative Pain; Mitral Valve Disease

Summary: patients scheduled for minimally invasive mitral valve replacement. each patient will be treated with intravenous (i.v.) oxycodone - patient-controlled analgesia (pca). half of the patients will be randomly allocated to erector spinae plane (esp) blockade group.

only patients who are qualified for an elective procedure of mitral valve replacement may participate in the study. each patient will be anesthetized generally. the same drugs will be used in each stage of anesthesia. the induction: etomidate, remifentanil, rocuronium, scolina as required. the maintenance: sevoflurane, remifentanil, rocuronium. the emergence: oxygen, sugammadex or neostigmine a required. patients will be randomly allocated into one of two groups: pca or esp. among the patients from esp group will have esp blockade before the induction of general anesthesia. esp blockade will be performed under ultrasound control. a single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 ml per patients' kg. the maximum dose is 40 ml. each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. pca with oxycodone (1mg/ml) will be utilized during the postoperative period: 5-minute interval. this is standard protocol in our department. only patients who are successfully awakened after the procedure may participate in the study. the pain intensity will be assessed with visual-analogue scale (vas) at 2, 4, 8, 12 and 24 hour after the end of anesthesia. the total consumption of oxycodone will be also monitored.

Eligibility criteria:
inclusion criteria: * scheduled mitral valve replacement surgery * obtained consent exclusion criteria: * allergy to oxycodone and local anesthetics * depression, antidepressant drugs treatment * epilepsy * usage of painkiller before surgery * addiction to alcohol or recreational drugs * postoperative ventilation or icu admission

Keywords: erector spinae plane blockade patient control anlagesia mitral valve replacement
italian lung cancer observational study

Conditions: Lung Cancer

Summary: lucent is an observational study focused on malignant pulmonary and tracheo-bronchial disease. it involves a large proportion of reference italian thoracic surgery centers. the relevance of the study is related to the epidemiology of lung cancer in the world - also known as "big killer" - and the high mortality rates both in males and females. the aim of his prospective study is to collect a large bulk of postoperative patients' outcome data and to produce up-to-date descriptive statistics of patients undergoing surgery for lung cancer. these results will be pivotal to compare the clinical results of all the relevant specialities involved in the care of lung cancer such as medical oncologists and radiation oncologists.


Eligibility criteria:
inclusion criteria: * patients with lung cancer * informed consent exclusion criteria: * alcohol or drug abuse * age \< 18 * inability to express consent